Aptorum Group Ltd
APMNasdaq
$7.00
↑ +1.1%Jul 17 close · end-of-day
Price
1Y↓ -63.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$51.5M
Enterprise Value
$51.5M
P/E
—
P/S
—
P/B
2.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$1.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-6.0%
ROIC
—
Debt / Equity
—
Net Cash
—
Return 1Y
-64.5%
Company profile
Aptorum Group Limited engages in the discovery, development, and commercialization of therapeutic products. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas.
- CEO
- Darren Lui
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Website
- www.aptorumgroup.com
Earnings
APM Q3 2025 Earnings
Period ends 2025-09-30
MetricActualYoY
Revenue——
Diluted EPS-$0.09↓ -25.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $1.5M | $1.3M | $431,378.00 | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | $4.9M | -$25.0M | -$9.8M | -$2.8M | -$4.3M | -$1.4M |
| Diluted EPS | $2.00 | -$7.15 | -$2.75 | -$0.62 | -$0.78 | -$0.19 |
| Operating cash flow | -$15.9M | -$14.7M | -$12.3M | -$7.7M | -$1.2M | -$1.8M |
| Free cash flow | -$16.1M | -$14.8M | -$12.5M | -$7.7M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | -1624.6% | -756.2% | -654.8% | — | — |
| Line item | Q3 '24 | Q3 '25 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | — | — |
| Net income | -$704,110.00 | -$613,995.00 |
| Diluted EPS | -$0.12 | -$0.09 |
| Operating cash flow | -$28,493.00 | -$484,283.00 |
| Free cash flow | — | — |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.